AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
Analyst coverage unavailable
Fundamentals
Fundamentals institutional score is 91 using growth durability 91.3.
Valuation
Valuation institutional score is 4 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
No usable analyst target or recommendation data was available.
Technical Structure
Technicals institutional score is 80 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 1 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation and market sentiment remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 43.5% above historical median. Valuation is stable — currently in the strongly overvalued zone (z-score: +1.61). Confidence: 79%.
Forward outlook is unavailable because live next-12-month estimate data is not available for this ticker right now.
5Y Average
12.19
Current
15.66
Overvalued
13.57
Undervalued
9.82
5Y Average
22.73
Current
29.19
Overvalued
26.37
Undervalued
19.11
5Y Average
5.03
Current
6.47
Overvalued
5.84
Undervalued
4.23
Peers & Comparison
Sector: Health Care · Theme: Biotechnology
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
PANACEA BIOTEC LTD PANACEABIOBiotechnology | +1.0% | -1.3% | — | — | -6.3% |
BIOGEN PHARMACHEM INDUSTRIES LTD BIOGEN PHARMACHEM INDUSTRIES LTDBiotechnology | — | — | — | — | — |
BIOCON LIMITED. BIOCONBiotechnology | +10.0% | 2.9% | 124.9x Premium | +29% vs avg | +20.1% |
ANTHEM BIOSCIENCES LTD ANTHEMBiotechnology | -22.6% | 28.7% | 84.0x Fair | -13% vs avg | +18.1% |
ONESOURCE SPECL PHARMA L ONESOURCEBiotechnology | +37.2% | -3.1% | — | — | -16.9% |
SAI LIFE SCIENCES LIMITED SAILIFEBiotechnology | +11.7% | 16.1% | 84.0x Fair | -13% vs avg | +60.0% |
ACUTAAS CHEMICALS LIMITED ACUTAASBiotechnology | +59.1% | 26.4% | 93.3x Fair | -3% vs avg | +149.2% |
SHEEL SHEELBiotechnology | — | — | — | — | — |
Comparable-scale peer data is limited — showing nearest stored business/industry peers instead of an empty comparison.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹73 CrJun 2026Latest net profit
₹15 CrJun 2026Latest EPS
₹17.29Jun 2026Net margin
34.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 80 | 66 | 66 | 73 | 73 | 74 | 63 | 77 | 63 | 65 | 70 | 94 | 73 |
| Expenses + | 69 | 54 | 54 | 60 | 60 | 59 | 54 | 63 | 51 | 53 | 54 | 62 | 48 |
| Operating Profit | 11 | 12 | 12 | 12 | 14 | 15 | 9 | 14 | 12 | 12 | 17 | 31 | 24 |
| OPM % | 14% | 18% | 18% | 17% | 18% | 20% | 14% | 18% | 20% | 18% | 24% | 34% | 34% |
| Other Income + | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 11 | 2 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 1 |
| Depreciation | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 5 |
| Profit before tax | 9 | 9 | 9 | 10 | 11 | 12 | 6 | 11 | 10 | 10 | 15 | 35 | 20 |
| Tax % | 26% | 26% | 25% | 27% | 25% | 25% | 32% | 16% | 24% | 27% | 27% | 24% | 26% |
| Net Profit + | 6 | 7 | 6 | 7 | 8 | 9 | 4 | 10 | 8 | 7 | 11 | 26 | 15 |
| EPS in Rs | 7.61 | 7.97 | 7.62 | 8.73 | 9.91 | 10.98 | 5.22 | 11.33 | 9.22 | 8.48 | 12.54 | 31.01 | 17.29 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome